Russian developers of Sputnik V urges the British-Sweden pharmaceutical AstraZeneca Company to combine its vaccine-candidate with the Russian one to increase the efficacy of the drug as Reuters reported.
“If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the #SputnikV human adenoviral vector shot to boost efficacy,” the developers of the Russian vaccine stated.
Recently, Russia stated that its Sputnik V vaccine has 92% efficacy in the protection of people from Covid-19 according to the interim trials. AstraZeneca reported that its vaccine’s efficiency is 70% and in particular cases, it might reach up to 90%.
Executive Director of AstraZeneca Pascal Soriot reported that the company seems to hold an additional global trial for the estimation of the efficiency of its vaccine after the number of issues that occurred after the last trial.
Besides, AstraZeneca plans to provide up to 200 million doses of its coronavirus vaccine by the end of 2020, and 700 million doses of the substance by the end of the first quarter of 2021.
#Covid latest update (November 27, 9 am, Kyiv time) pic.twitter.com/hMvBDyUfoj
— 112 News (@112NewsFeed) November 27, 2020
